Advertisement

 

 

Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset?

Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset?
Author Information (click to view)

Sahli ZT, Umbricht CB, Schneider EB, Zeiger MA,


Sahli ZT, Umbricht CB, Schneider EB, Zeiger MA, (click to view)

Sahli ZT, Umbricht CB, Schneider EB, Zeiger MA,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Thyroid : official journal of the American Thyroid Association 2017 09 2827(11) 1393-1399 doi 10.1089/thy.2017.0238

Abstract
BACKGROUND
Current thyroid molecular tests are specifically designed for the differential diagnosis of nodules with indeterminate or suspicious fine-needle aspiration (FNA) cytology.

SUMMARY
However, their clinical validity faces challenges from both variation among institutions in cancer prevalence and, most recently, the new category of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The latter diagnosis was previously classified as malignant. Relevant to this, all molecular panels on the market today were originally tested and validated within the context of these entities being considered malignant.

CONCLUSION
This review examines possible effects of the NIFTP reclassification as a precancerous lesion on the original validation studies and, investigates the effect of the significant reported variability in thyroid cancer prevalence on the performance of these tests.

Submit a Comment

Your email address will not be published. Required fields are marked *

10 + fifteen =

[ HIDE/SHOW ]